Literature DB >> 10523016

Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas.

S M Webb1, M Rigla, A Wägner, B Oliver, F Bartumeus.   

Abstract

Surgery is the treatment of choice for many pituitary tumors; pituitary function may suffer after operation, but relief of pressure on the normal pituitary may also favor postoperative recovery of hypopituitarism. The aim of this study was to investigate the frequency of new appearance and recovery of hypopituitarism after neurosurgery and try to identify features associated with it. Pre- and postoperative anterior pituitary functions were investigated in 234 patients with pituitary adenomas (56 nonfunctioning, 71 PRL-secreting, 66 GH-secreting, 39 ACTH-secreting, 1 LH/FSH-secreting, and 1 TSH-secreting tumors). Eighty-eight new postoperative pituitary hypofunctions appeared in 52 patients (12 NF, 14 PRL-secreting, 15 GH-secreting, 10 ACTH-secreting, and 1 LH/FSH-secreting adenomas). They corresponded to 27% ACTH deficiencies (in 29 of the 107 patients with normal preoperative ACTH in whom postoperative evaluation was complete), 14.5% (15 of 103) new GH deficiencies, 10.5% (15 of 143; P < 0.0005, significantly less than ACTH deficiency) new TSH deficiencies, 16.5% (20 of 121) new gonadotropin deficiencies, and 13% (9 of 71) new PRL deficiencies. Preoperatively, 93 were deficient in at least 1 pituitary hormone; after surgery, 45 (48%) recovered between 1 and 3 hormones. The 2 patients with LH/FSH- and TSH-secreting macroadenomas did not recover pituitary function. Factors associated with a higher probability of postoperative pituitary function recovery were: no tumor rests on postoperative pituitary imaging (P = 0.001) and no neurosurgical (P = 0.001) or pathological evidence (P = 0.049) of an invasive nature. Tumor size did not differ significantly between those who did and those who did not recover pituitary function after surgery. Even if clear hypofunction is observed at initial work-up, patients should be reassessed after surgery without substitution therapy, because practically half the preoperative pituitary hormone deficiencies recover postoperatively, eliminating the need for life-long substitution therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523016     DOI: 10.1210/jcem.84.10.6019

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Is vascular mortality increased in hypopituitarism?

Authors:  E M Erfurth; B Bülow; L E Hagmar
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

2.  Immediate and delayed postoperative morbidity in functional and non-functioning pituitary adenomas.

Authors:  Anna Aulinas; Cristina Colom; Juan Ybarra; Fernando Muñoz; Pere Tresserras; Eugenia Resmini; Susan M Webb
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 3.  Treatment of pituitary tumors: surgery.

Authors:  Michael Buchfelder
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

4.  Endocrine alterations in critically ill patients with stroke during the early recovery period.

Authors:  Ioanna Dimopoulou; Andreas T Kouyialis; Stylianos Orfanos; Apostolos Armaganidis; Marinella Tzanela; Nikolaos Thalassinos; Stylianos Tsagarakis
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

6.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas.

Authors:  Orsalia Alexopoulou; Valérie Everard; Martine Etoa; Edward Fomekong; Stéphane Gaillard; Fabrice Parker; Christian Raftopoulos; Philippe Chanson; Dominique Maiter
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

Review 7.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

Review 8.  Guidelines in the management of CNS tumors.

Authors:  Navid Redjal; Andrew S Venteicher; Danielle Dang; Andrew Sloan; Remi A Kessler; Rebecca R Baron; Constantinos G Hadjipanayis; Clark C Chen; Mateo Ziu; Jeffrey J Olson; Brian V Nahed
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

9.  Intraoperative unfolding and postoperative pruning of the pituitary gland after transsphenoidal surgery for pituitary adenoma: A volumetric and endocrinological evaluation.

Authors:  Victor E Staartjes; Sarah Stricker; Giovanni Muscas; Nicolai Maldaner; David Holzmann; Jan-Karl Burkhardt; Burkhardt Seifert; Christoph Schmid; Carlo Serra; Luca Regli
Journal:  Endocrine       Date:  2018-09-21       Impact factor: 3.633

10.  Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.

Authors:  Christine G Yedinak; Isabelle Cetas; Alp Ozpinar; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2016-07-26       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.